Organon & Co. (ogn)
OGN Earnings
Public earnings and growth snapshot for Organon & Co.. Full earnings calendars, surprises, and multi-year history are available in Vest Terminal.
| Earnings growth (YoY) | -28.3% |
| Revenue growth (YoY) | -2.3% |
| Trailing P/E | 17.60 |
| Forward P/E | 3.80 |
| Last price | $13.73 |
| Market cap | $3.61B |
Start Free — open OGN in Vest Terminal
Access live data, filings, ownership, and analysis for Organon & Co..
Organon & Co. FAQ
What does Organon & Co. (OGN) do?
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's…
What is OGN's P/E ratio?
Organon & Co. has a trailing P/E of 17.60× based on publicly available market data.
Does OGN pay a dividend?
Indicated dividend yield: 0.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is OGN in?
Organon & Co. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is OGN's market capitalization?
Approximate market cap: $3.61B.
What are the main risks for OGN?
Key risks include above-average volatility (beta 1.52), negative revenue growth, among factors on this page.
What are the strengths of OGN?
Potential positives include return on equity near 24.0% — efficient use of shareholder capital, gross margin of 53.4% supports competitive unit economics.
Where can I get analyst estimates for OGN?
Public analyst price targets and consensus for Organon & Co. are on the free /stocks/ogn/estimates page. Deeper estimate history and models are available in Vest Terminal.